Menu
Close
Stories & News
Resources
Stay Informed
x
Stay Informed
November 10, 2021
Pfizer’s investigational novel COVID-19 oral antiviral candidate, PAXLOVID ™ (PF-07321332; ritonavir), reduced the risk of COVID-19-related hospitalization or death from any cause by 89 percent in a study in patients treated within three days of symptom onset, according to the company.
Pfizer will seek emergency use authorization from the U.S. FDA for the treatment candidate as soon as possible.
“Today’s news is a real game-changer in the global efforts to halt the devastation of this pandemic. These data suggest that our oral antiviral candidate, if approved or authorized by regulatory authorities, has the potential to save patients’ lives, reduce the severity of COVID-19 infections, and eliminate up to nine out of ten hospitalizations,” said Albert Bourla, Chairman and Chief Executive Officer, Pfizer.
If authorized, PAXLOVID would be the first oral antiviral of its kind, a specifically designed SARS-CoV-2-3CL protease inhibitor.
For more detail, read our press release.
Forward-looking statements included herein are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. We encourage you to read our reports filed with the U.S. Securities and Exchange Commission (SEC), including the sections captioned “Risk Factors” and “Forward Looking Information and Factors that May Affect Future Results,” for a description of such substantial risks and uncertainties. These reports are available at pfizer.com and the SEC’s website.
Copyright © 2002 – 2025 Pfizer Investor Insights All rights reserved. This information—including product information—is intended only for residents of the United States. The products discussed herein may have different labeling in different countries. This website contains certain information about Pfizer, but may not contain all information that is material to Pfizer.